Please ensure Javascript is enabled for purposes of website accessibility

22nd Century Group Inc. Surged 26% in September. Here's Why

By Cory Renauer - Updated Oct 4, 2017 at 11:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA's push to reduce nicotine consumption is especially well-timed for the tiny biotechnology company.

What happened

Shares of 22nd Century Group Inc. (XXII -1.32%), a small-cap biotechnology company focused on tobacco, rose 25.9% in September, according to data from S&P Global Market Intelligence. The Food and Drug Administration's plan to reduce cigarette nicotine levels has been boosting the stock all year, and more good news about the company's intellectual property kept the party going last month.

So what 

This summer, recently appointed FDA Commissioner Scott Gottlieb outlined a plan to finally use powers granted by the Family Smoking Prevention and Tobacco Control Act. The law, enacted in 2009, gives the agency the power to regulate levels of nicotine and other harmful compounds that cigarette smokers inhale each day.

Plants growing on top of coins stacked in the shape of an upward-sloping chart.

Image source: Getty Images.

How would 22nd Century Group benefit from potential regulation? The company claims its patent portfolio makes it "the only company" on the planet capable of supplying America's $130 billion tobacco industry with leaves that contain nonaddictive nicotine levels. An agreement with British American Tobacco that had been preventing the company from seeking new partnerships came to an end last month.

Now what

Without a doubt, 22nd Century Group's patent portfolio positions the company for explosive gains, but that doesn't mean the stock isn't terribly risky. The not-yet-profitable company's market cap has more than doubled to $292.4 million since Gottlieb announced the FDA's renewed interest in tobacco regulation, even though the company has yet to book any revenue from its proprietary very-low-nicotine tobacco. 

If the FDA quietly abandons plans to lower cigarette nicotine levels, 22nd Century would be left with products such as filtered cigars, which it can't seem to sell at a profit. Although product sales are on the rise, the company's cost of goods sold came in at 104.2% of net sales revenue in the second quarter.

Although the general public would like to see the FDA finally use powers enacted eight years ago under President Obama while Democrats controlled Congress, forcing the tobacco industry to fill cigarettes with low-nicotine tobacco is just the sort of regulatory overreach vehemently opposed by the Trump administration. Given the administration's unpredictability, it might be best to watch this story unfold from a safe distance.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

22nd Century Group, Inc. Stock Quote
22nd Century Group, Inc.
XXII
$2.24 (-1.32%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.